BACKGROUND: Central nervous system (CNS) relapse is an uncommon but dramatic complication of diffuse large B-cell lymphoma (DLBCL). Several studies have demonstrated the superiority of cerebrospinal fluid (CSF) flow cytometry (FCM), as compared with conventional cytology (CC), in detecting occult leptomeningeal disease. The clinical relevance of a positive FCM still has to be clarified. PATIENTS AND METHODS: We analyzed CSF from 114 DLBCL patients at diagnosis (n = 95) or at relapse (n = 19) by FCM and CC. Most patients received meningeal prophylaxis. FCM results did not influence treatment strategies. RESULTS: Fourteen samples were FCM+, versus one CC+ (also FCM+). Within all patients without neurological symptoms (n = 101), four (4%) relapsed in the CNS, with a median time to relapse of 5.2 months. Only one-fourth (25%) was FCM+ before relapse. More than one extranodal disease site and elevated lactate dehydrogenase levels were associated with an increased risk of CNS relapse. CONCLUSIONS: FCM gives far more positive results than CC. However, a positive FCM result did not translate into a significant increase in CNS relapse rate in this histologically uniform population receiving CNS prophylaxis.
BACKGROUND: Central nervous system (CNS) relapse is an uncommon but dramatic complication of diffuse large B-cell lymphoma (DLBCL). Several studies have demonstrated the superiority of cerebrospinal fluid (CSF) flow cytometry (FCM), as compared with conventional cytology (CC), in detecting occult leptomeningeal disease. The clinical relevance of a positive FCM still has to be clarified. PATIENTS AND METHODS: We analyzed CSF from 114 DLBCL patients at diagnosis (n = 95) or at relapse (n = 19) by FCM and CC. Most patients received meningeal prophylaxis. FCM results did not influence treatment strategies. RESULTS: Fourteen samples were FCM+, versus one CC+ (also FCM+). Within all patients without neurological symptoms (n = 101), four (4%) relapsed in the CNS, with a median time to relapse of 5.2 months. Only one-fourth (25%) was FCM+ before relapse. More than one extranodal disease site and elevated lactate dehydrogenase levels were associated with an increased risk of CNS relapse. CONCLUSIONS: FCM gives far more positive results than CC. However, a positive FCM result did not translate into a significant increase in CNS relapse rate in this histologically uniform population receiving CNS prophylaxis.
Authors: D Subirá; M Simó; J Illán; C Serrano; S Castañón; R Gonzalo; J J Granizo; M Martínez-García; M Navarro; J Pardo; J Bruna Journal: Clin Exp Metastasis Date: 2015-03-21 Impact factor: 5.150
Authors: Sang Yong Shin; Seung Tae Lee; Hee Jin Kim; Young Lyun Oh; Seok Jin Kim; Won Seog Kim; Sun Hee Kim Journal: Ann Lab Med Date: 2016-05 Impact factor: 3.464
Authors: Iole Cordone; Serena Masi; Valentina Summa; Mariantonia Carosi; Antonello Vidiri; Alessandra Fabi; Alessia Pasquale; Laura Conti; Immacolata Rosito; Carmine Maria Carapella; Veronica Villani; Andrea Pace Journal: Breast Cancer Res Date: 2017-04-11 Impact factor: 6.466
Authors: Adam J Olszewski; Anna D Chorzalska; Max Petersen; Thomas A Ollila; Adam Zayac; Habibe Kurt; Diana O Treaba; John L Reagan; Andrew Hsu; Pamela C Egan; James Butera; Rabin Niroula; John Vatkevich; Jordan Robison; Ilyas Sahin; Allison P Jacob; Chelsea D Mullins; Patrycja M Dubielecka Journal: Blood Adv Date: 2021-12-28